FDA Expands Use Of Remdesivir To Patients With High Risk Of Hospitalization

PARIS, France – The U.S. health regulator on Friday expanded its approval for the use of Gilead Sciences’ antiviral drug remdesivir to treat non – hospitalized patients 12 years and older for the treatment of mild – to – moderate COVID -19 disease with high risk of hospitalization.

Previously, the use of Veklury was limited to patients requiring hospitalization.